Yahoo · Nov 2, 2026
Why Indivior Pharmaceuticals Stock Topped the Market Today
The company is merging with a peer.
SU
NASDAQ · SUPN
Supernus Pharmaceuticals, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$28.15
Up+$0.00 (+0.00%)
Updated Nov 4, 2026, 2:25 AM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.6B
- P/E ratio
- -137.62
- Dividend yield
- 0.00%
- 52-week range
- $37.54 – $59.68
- Volume
- 9.06M
- Avg. volume
- 851.65K
Price performance · SUPN
SUPN price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
SUPN closed at $28.15 after 20 trading sessions, down 34.28% for the selected period.
- Last close
- $28.15
- Period change
- -34.28%
- Period low
- $28.15
- Period high
- $43.05
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $28.35 | $31.62 | $27.97 | $28.15 | 9.06M |
| Oct 30, 2026 | $42.07 | $43.72 | $39.53 | $41.92 | 2.82M |
| Oct 29, 2026 | $44.24 | $44.31 | $40.75 | $41.84 | 1.89M |
| Oct 28, 2026 | $40.46 | $41.18 | $39.67 | $41.08 | 1.1M |
| Oct 27, 2026 | $40.57 | $41.20 | $39.87 | $40.96 | 1.08M |
| Oct 26, 2026 | $40.72 | $40.87 | $39.575 | $40.77 | 930.9K |
| Oct 23, 2026 | $41.68 | $41.95 | $39.9575 | $40.70 | 1.16M |
| Oct 22, 2026 | $41.52 | $42.09 | $40.73 | $42.07 | 937.42K |
| Oct 21, 2026 | $41.23 | $42.00 | $40.86 | $41.21 | 1.01M |
| Oct 20, 2026 | $39.95 | $41.74 | $39.77 | $41.23 | 1.24M |
| Oct 19, 2026 | $37.77 | $40.52 | $37.765 | $39.84 | 1.51M |
| Oct 16, 2026 | $39.49 | $39.50 | $37.54 | $37.88 | 1.44M |
| Oct 15, 2026 | $40.21 | $41.31 | $39.36 | $39.57 | 1.01M |
| Oct 14, 2026 | $41.93 | $43.26 | $39.97 | $40.18 | 906.72K |
| Oct 13, 2026 | $42.94 | $43.29 | $41.71 | $42.01 | 1.2M |
| Oct 12, 2026 | $42.67 | $43.20 | $41.90 | $42.81 | 914.56K |
| Oct 9, 2026 | $42.18 | $43.14 | $42.15 | $42.67 | 643.83K |
| Oct 8, 2026 | $42.41 | $43.405 | $41.135 | $42.14 | 684.16K |
| Oct 7, 2026 | $42.24 | $43.38 | $42.24 | $43.05 | 571.04K |
| Oct 6, 2026 | $42.86 | $43.12 | $41.40 | $42.83 | 748.26K |
Latest SUPN news
The latest Smart Investors Daily articles mentioning SUPN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
SUPN research
Overview
Company profile and research snapshot.
Company profile
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $64.00
- Implied upside
- —
- Analysts
- 12
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 9, 2026 | Cantor Fitzgerald | Overweight | — |
| Dec 19, 2025 | Stifel | Hold | — |
| Oct 29, 2025 | B of A Securities | Buy | — |
| Oct 23, 2025 | TD Cowen | Buy | — |
| Oct 9, 2025 | Piper Sandler | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Nov 2, 2026
Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader
Merger positions Supernus as a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, enhanced financial flexibility and a differentiated pipelineSignificantly enhances cash flow profile and scale, unlocking greater capacity to resource growth-driving products, advance CNS pipeline, and pursue strategic opportunitiesCombined entity will operate as Supernus, Inc. and begin trading on the Nasdaq Global Market under the ticker symbol
Yahoo · Nov 1, 2026
SUPN Q3 deep dive: robust portfolio growth and integration priorities amid Indivior merger
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) announced better-than-expected revenue in Q3 2026, with sales up 18.1% year on year to $226.8 million. The company’s full-year revenue guidance of $887.5 million at the midpoint came in 1.5% above analysts’ estimates. Its non-GAAP profit of $0.88 per share was 79.2% above analysts’ consensus estimates.
Yahoo · Oct 30, 2026
Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Turnaround Narrative
Indivior Pharmaceuticals (INDV) moved back into focus after reporting record third quarter earnings and reaffirming its 2026 revenue outlook. This gave investors fresh numbers to weigh alongside an approved merger with Supernus Pharmaceuticals. Over the past year Indivior Pharmaceuticals has combined a 56.53% total shareholder return with a share price near US$35.37 that has eased 11.60% over the last 90 days, suggesting long term holders have been rewarded while shorter term momentum has...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
